IFOM

Academic/HospitalWebsite ↗

Also known as: IFOM ETS - The AIRC Institute of Molecular Oncology | IFOM (Istituto FIRC di Oncologia Molecolare) | IFOM, The FIRC Institute of Molecular Oncology

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Mar 1, 2018

Last known activity

Oct 22, 2024

Timeline

No events for the selected filters.

Drugs by trial phase (21 distinct, 7 trials)

Phase 3 (11 own, 0 via acquisition)

irinotecan
fluorouracil
nivolumab
leucovorin
trastuzumab
panitumumab
ipilimumab
pertuzumab
temozolomide
capecitabine
oxaliplatin

Phase 2 (10 own, 0 via acquisition)

metformin
atezolizumab
doxorubicin
durvalumab
paclitaxel
pembrolizumab
propranolol
cyclophosphamide
levoleucovorin
ceralasertib

Indications

Studied for

Breast Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
Congenital Abnormalities
Hemangioma, Cavernous, Central Nervous System
Microsatellite Instability
Triple Negative Breast Neoplasms

Recent trials (9)

NCT06490536Lead sponsorPhase 3Oct 22, 2024
NCT05703997CollaboratorPhase 2Jan 31, 2023
NCT05582538Lead sponsorPhase 2Nov 30, 2022
NCT04259944Lead sponsorPhase 2Mar 15, 2020
NCT04248998CollaboratorPhase 2Mar 1, 2020
NCT03519412Lead sponsorPhase 2Sep 30, 2018
NCT03519412Study directorPhase 2Sep 30, 2018
NCT03589014Study chairPhase 2Mar 1, 2018
NCT03589014CollaboratorPhase 2Mar 1, 2018

Details

Founded: Milan, IT
Last known activity: Oct 22, 2024